

Table 2 NAI susceptibility of influenza B/Yamagata isolates by fluorescent NAI assay

NAIs	Origin of specimen	No. analysed	IC ₅₀ (nM)		
			Median (range)	Mean ± SD	NAI susceptibility (fold change)
<i>Oseltamivir</i>	ILI	28	33.94 (11.60–46.44)	31.98 ± 9.57	S (I)
	SARI	30	31.84 (12.04–59.01)	31.52 ± 11.17	S (I)
		2	225.40 (200.60–250.20)	225.44±35.07	RS (6–8)
<i>Zanamir</i>	ILI	28	3.45 (0.67–7.51)	3.37 ± 1.79	S (I)
	SARI	32	3.60 (0.56–8.61)	3.74 ± 2.11	S (I)

Median IC₅₀ values for the drug among susceptible viruses (outliers excluded in calculation).

IC₅₀ values calculated using JASPER curve-fitting software.

Mean and SD of IC₅₀ values for the drug among susceptible viruses (outliers excluded in calculation).

Fold changes in IC₅₀ determined by comparing IC₅₀ of test viruses to the mean IC₅₀ (outliers excluded) by respective drug and influenza type/subtype.

ILI – influenza-like illness; NAI – neuraminidase inhibitor; RS – reduced susceptibility; S – sensitive; SARI – severe acute respiratory illness; SD – standard deviation.